Current Rheumatology Reports

, Volume 7, Issue 3, pp 235–241

Recent advances in the epidemiology of gout

  • Kenneth G. Saag
  • Ted R. Mikuls


Gout remains among the most common of all inflammatory arthridities with an incidence that appears to have risen. Evidence is accumulating to support lifestyle and dietary factors, such as heavy consumption of beer and liquor as well as diets rich in meats and seafood as important gout risk factors. There is also a renewed interest in important associations between gout and other comorbidities like hypertension and cardiovascular disease. The importance of hyperuricemia on health considerations beyond the musculoskeletal system is an area worthy of even more study.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Currie W: Prevalence and incidence of the diagnosis of gout in Great Britain. Ann Rheum Dis 1979, 38:101–106.PubMedCrossRefGoogle Scholar
  2. 2.
    Harris C, Lloyd C, Lewis J: The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995, 48:1153–1158.PubMedCrossRefGoogle Scholar
  3. 3.
    Mikuls T, Farrar J, Bilker W, et al.: Gout epidemiology: results from the U.K. General Practice Research Database, 1990–1999. Ann Rheum Dis 2005, 64:267–272. Recently updated incidence and prevalence estimates based on data analysis from the electronic medical record of a sizable population of patients followed-up by generalists in the United Kingdom.PubMedCrossRefGoogle Scholar
  4. 4.
    Klemp P, Stansfield S, Castle B, Robertson M: Gout is on the increase in New Zealand. Ann Rheum Dis 1997, 56:22–26.PubMedCrossRefGoogle Scholar
  5. 5.
    Prior I, Rose B: Uric acid, gout and public health in the South Pacific. NZ Med J 1966, 65:295–300.Google Scholar
  6. 6.
    Benson V, Marano M: Current estimates from the National Health Interview Survey, 1992. Vital Health Stat 1992, 189:1–269.Google Scholar
  7. 7.
    Lawrence R, Helmick C, Arnett F, et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778–799.PubMedCrossRefGoogle Scholar
  8. 8.
    Lawrence R, Hochberg M, Kelsey J, et al.: Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989, 16:427–441.PubMedGoogle Scholar
  9. 9.
    Abbott RD, Brand FN, Kannel WB, Castelli WP: Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 1988, 41:237–242.PubMedCrossRefGoogle Scholar
  10. 10.
    Hall A, Barry P, Dawber T, McNamara P: Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med 1967, 42:27–37.PubMedCrossRefGoogle Scholar
  11. 11.
    O’Sullivan J: Gout in a New England town: a prevalence study in Sudbury, Massachusetts. Ann Rheum Dis 1972, 31:166–169.PubMedCrossRefGoogle Scholar
  12. 12.
    Aromdee E, Michet C, Crowson C, et al.: Epidemiology of gout: is the incidence rising? J Rheumatol 2002, 29:2403–2406. An excellent epidemiologic study using the Rochester Epidemiology Cohort demonstrating variable rates of gout over time.Google Scholar
  13. 13.
    Mikuls T, Farrar J, Bilker W, et al.: Gout epidemiology: results from the U.K. General Practice Research Database, 1990–1999. Ann Rheum Dis 2005, 64:267–272.PubMedCrossRefGoogle Scholar
  14. 14.
    Roubenoff R, Klag M, Mead L, et al.: Incidence and risk factors for gout in white men. JAMA 1991, 266:3004–3007.PubMedCrossRefGoogle Scholar
  15. 15.
    Campion E, Glynn R, DeLabry L: Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987, 82:421–426.PubMedCrossRefGoogle Scholar
  16. 16.
    Stewart O, Silman A: Review of UK data on the rheumatic diseases-4 Gout. Br J Rheumatol 1990, 29:485–488.PubMedCrossRefGoogle Scholar
  17. 17.
    Fam A: Gout in the elderly: clinical presentation and treatment. Drugs Aging 1998, 13:229–243.PubMedCrossRefGoogle Scholar
  18. 18.
    Bieber J, Terkeltaub R: On the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004, 50:2400–2414.PubMedCrossRefGoogle Scholar
  19. 19.
    Fang J, Alderman M: Serum uric acid and cardiovascular mortality: NHANES I epidemiologic follow-up study, 1971–1992. JAMA 2000, 283:2404–2410. A secondary analysis of a large, highly generalizable, national survey that showed an increased risk for cardiovascular mortality among person with higher uric acid levels.PubMedCrossRefGoogle Scholar
  20. 20.
    Hochberg M, Thomas J, Thomas D, et al.: Racial differences in the incidence of gout: the role of hypertension. Arthritis Rheum 1995, 38:628–632.PubMedCrossRefGoogle Scholar
  21. 21.
    Burke G, Jacobs D, Sprafka J, et al.: Obesity and overweight in young adults: the CARDIA study. Prev Med 1990, 19:476–488.PubMedCrossRefGoogle Scholar
  22. 22.
    US Renal Data System. USRDS 1999 annual data report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.Google Scholar
  23. 23.
    Choi H, Atkinson K, Karlson E, et al.: Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004, 350:1093–1103. An investigation using the Health Professionals Follow-up Study showing provocative associations of animal but not vegetable food sources of purines with goutPubMedCrossRefGoogle Scholar
  24. 24.
    Garrel D, Verdy M, PetitClerc C, et al.: Milk- and soy-protein ingestion: acute effect on serum uric acid concentration. Am J Clin Nutr 1991, 53:665–669.PubMedGoogle Scholar
  25. 25.
    Ghadirian P, Shatenstein B, Verdy M, Hamet P: The influence of dairy products on plasma uric acid in women. Eur J Epidemiol 1995, 11:275–281.PubMedCrossRefGoogle Scholar
  26. 26.
    Blau L: Cherry diet control for gout and arthritis. Tex Rep Biol Med 1950, 8:309–311.PubMedGoogle Scholar
  27. 27.
    Jacob R, Spinozzi G, Simon V, et al.: Consumption of cherries lowers plasma urate in healthy women. J Nutr 2003, 133:1826–1829.PubMedGoogle Scholar
  28. 28.
    Choi H, Atkinson K, Karlson E, et al.: Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004, 363:1277–1281. Another paper using the Health Professionals Follow-up Study demonstrating higher risk for gout with increased exposure to beer and spirits but not with winePubMedCrossRefGoogle Scholar
  29. 29.
    Shadick N, Kim R, Weiss S, et al.: Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol 2000, 27:1708–1712. The development of gout due to high levels of lead exposure (saturine gout) is an association of long reported interest. This paper highlights a newer interest in gout risk after lower level lead exposure.PubMedGoogle Scholar
  30. 30.
    Gibson T, Rodgers A, Simmonds H, Toseland P: Beer drinking and its effect on uric acid. Br J Rheumatol 1984, 23:203–209.PubMedCrossRefGoogle Scholar
  31. 31.
    Choi HK, Curhan G: Beer, liquor, and wine consumption and serum uric acid level: The third National Health and Nutrition Examination Survey. Arthritis Rheum 2004, 51:1023–1029. In this large U.S. population-based survey, a significant and positive relationship was confirmed between high alcoholic beverage consumption and greater levels of uric acid.PubMedCrossRefGoogle Scholar
  32. 32.
    Lin J-L, Tan D-T, Ho H-H, Yu C-C: Environmental lead exposure and urate excretion in the general population. Am J Med 2002, 113:563–568. Body lead burden increased a persons gout risk based on this cross-sectional Taiwanese data.PubMedCrossRefGoogle Scholar
  33. 33.
    Langford HG, Blaufox MD, Borhani NO, et al.: Is thiazideproduced uric acid elevation harmful: analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987, 147:645–649.PubMedCrossRefGoogle Scholar
  34. 34.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2987.CrossRefGoogle Scholar
  35. 35.
    Burack DA, Griffith BP, Thompson ME, Kahl LE: Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med 1992, 92:141–146.PubMedCrossRefGoogle Scholar
  36. 36.
    Chapman JR, Harding NGL, Griffiths D, Morris PJ: Reversibility of cyclosporin nephrotoxicity after three months’ treatment. Lancet 1985, 325:128–130.CrossRefGoogle Scholar
  37. 37.
    Clive DM: Renal transplant-associated hyperurecemia and gout. J Am Soc Nephrol 2000, 11:974–979.PubMedGoogle Scholar
  38. 38.
    Lin HY, Rocher LL, McQuillan MA, et al.: Cyclosporineinduced hyperuricemia and gout. N Engl J Med 1989, 321:287–292.PubMedCrossRefGoogle Scholar
  39. 39.
    Ahn KJ, Kim YS, Lee HC, et al.: Cyclosporine-induced hyperuricemia after renal transplant: clinical characteristics and mechanisms. Transplant Proc 1992, 24:1391–1392.PubMedGoogle Scholar
  40. 40.
    Caspi D, Lubart E, Graff E, et al.: The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000, 43:103–108.PubMedCrossRefGoogle Scholar
  41. 41.
    Gertler MM, Gam SM, Levine SA: Serum uric acid in relation to age and physique in health and coronrary heart disease. Ann Intern Med 1951, 34:1421–1431.PubMedGoogle Scholar
  42. 42.
    Scott JT, Sturge RA: The effect of weight loss on plasma and urinary uric acid and lipid levels. J Clin Chem Clin Biochem 1976, 14:319.Google Scholar
  43. 43.
    St-Onge MP, Keller KL, Heymsfield SB: Changes in childhood food consumption patterns: a cause for concern in light of increasing body weights. Am J Clin Nutr 2003, 78:1068–1073.PubMedGoogle Scholar
  44. 44.
    Bedir A, Topbas M, Tanyeri F, et al.: Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J 2003, 44:527–536. This study provides a provocative glimpse into a potential biological mechanism that could help explain the association between obesity and gout.PubMedCrossRefGoogle Scholar
  45. 45.
    Denzer C, Muche R, Mayer H, et al.: Serum uric acid levels in obese children and adolescents: linkage to testosterone levels and pre-metabolic syndrome. J Pediatr Endocrinol Metab 2003, 16:1225–1232.PubMedGoogle Scholar
  46. 46.
    Nakanishi N, Tatara K, Nakamura K, Suzuki K: Risk factors for the incidence of hyperuricaemia: a 6-year longitudinal study of middle-aged Japanese men. Int J Epidemiol 1988, 28:888–893.CrossRefGoogle Scholar
  47. 47.
    Breckenridge A: Hypertension and hyperuricaemia. Lancet 1966, 1:15–18.PubMedCrossRefGoogle Scholar
  48. 48.
    Gavin AR, Struthers AD: Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2003, 3:309–314.PubMedCrossRefGoogle Scholar
  49. 49.
    Feig DI, Johnson RJ: Hyperuricemia in childhood primary hypertension. Hypertension 2003, 42:247–252.PubMedCrossRefGoogle Scholar
  50. 50.
    Tykarski A: Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991, 59:364–368.PubMedCrossRefGoogle Scholar
  51. 51.
    Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al.: Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002, 283:F1105–1110. An elegant physiologic study suggesting that hyperuicemia in rats may play a direct pathogenic role as a mechanism that could potentially explain a documented association of gout with hypertension in man.PubMedGoogle Scholar
  52. 52.
    Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J: Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988, 224:549–555.PubMedCrossRefGoogle Scholar
  53. 53.
    Freedman DS, Williamson DF, Gunter EW, Byers T: Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995, 141:637–644.PubMedGoogle Scholar
  54. 54.
    Levine W, Dyer AR, Shekelle RB, et al.: Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol 1989, 42:257–267.PubMedCrossRefGoogle Scholar
  55. 55.
    Woo J, Swaminathan R, Cockram C, et al.: Association between serum uric acid and some cardiovascular risk factors in a Chinese population. Postgrad Med J 1994, 70:486–491.PubMedCrossRefGoogle Scholar
  56. 56.
    Brand FN, McGee DL, Kannel WB, et al.: Hyperuricemia as a risk factor of coronary heart disease: the Framingham study. Am J Epidemiol 1985, 121:11–18.PubMedGoogle Scholar
  57. 57.
    Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131:7–13.PubMedGoogle Scholar
  58. 58.
    Gelber AC, Klag MJ, Mead LA, et al.: Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med 1997, 157:1436–1440.PubMedCrossRefGoogle Scholar
  59. 59.
    Persky VW, Dyer AR, Idris-Soven E, et al.: Uric acid: a risk factor for coronary heart disease? Circulation 1979, 59:969–977.PubMedGoogle Scholar
  60. 60.
    Rathmann W, Funkhouser E, Dyer AR, Roseman JM: Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Ann Epidemiol 1998, 8:250–261.PubMedCrossRefGoogle Scholar
  61. 61.
    Høieggen A, Alderman MH, Kjeldsen SE, et al.: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004, 65:1041–1049. A randomized controlled clinical trial of Losartan demonstrating a modest uricosuric effect and a perceived resultant lower risk for cardiovascular events.PubMedCrossRefGoogle Scholar
  62. 62.
    Lehto S, Niskanen L, Ronnemaa T, Laakso M: Serum uric acid is a strong predictor of stroke in patients with non-insulindependent diabetes mellitus. Stroke 1998, 29:635–639.PubMedGoogle Scholar
  63. 63.
    Anker SD, Doehner W, Rauchhaus M, et al.: Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003, 107:1991–1997. This study suggests important associations of hyperuricemia with congestive heart failure.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Kenneth G. Saag
    • 1
  • Ted R. Mikuls
  1. 1.Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations